Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CTI Spin-Off Aims To Put Follow-On Biologics In The Clinic Within Two Years

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen products eyed as initial candidates, exec tells “The Pink Sheet” DAILY.

You may also be interested in...



CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana

New firm’s management team is looking for pharma partners to validate its expertise, attract venture funding while parent CTI struggles to stay in business.

CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana

New firm’s management team is looking for pharma partners to validate its expertise, attract venture funding while parent CTI struggles to stay in business.

Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon

Abraxis BioScience and Biocon have signed a licensing agreement that gives the Los Angeles firm the right to develop a biosimilar of granulocyte-colony stimulating factor in North America and the European Union, the companies announced July 19

Related Content

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel